指南与共识哮喘

欧洲呼吸学会轻度哮喘按需ICS/福莫特罗使用短指南

European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma.
指南 / 共识 · Eur Respir J · 2023-10-12

欧洲呼吸学会成立工作组,采用GRADE方法评估两个问题,制定轻度哮喘按需ICS/福莫特罗使用的循证推荐。工作组建议成人和青少年轻度哮喘使用按需ICS/福莫特罗而非按需SABA(强推荐,低确定性证据);成人可用按需ICS/福莫特罗替代规律ICS维持加按需SABA(条件推荐,低确定性证据),青少年两种方案均可。

要点

  • 成人及青少年轻度哮喘推荐按需ICS/福莫特罗而非按需SABA(强推荐,低确定性证据)。
  • 成人轻度哮喘可用按需ICS/福莫特罗替代规律ICS维持加按需SABA(条件推荐,低确定性证据)。
  • 青少年轻度哮喘可选按需ICS/福莫特罗或ICS维持加按需SABA(条件推荐,低确定性证据)。

核心结论

  • 成人及青少年轻度哮喘推荐使用按需ICS/福莫特罗而非按需SABA(强推荐,低确定性证据)。
  • 成人轻度哮喘建议使用按需ICS/福莫特罗而非规律ICS维持加按需SABA(条件推荐,低确定性证据)。
  • 青少年轻度哮喘建议使用按需ICS/福莫特罗或ICS维持加按需SABA均可(条件推荐,低确定性证据)。

研究设计与样本

  • 欧洲呼吸学会成立工作组,采用GRADE方法评估两个问题并制定推荐。

主要发现

  • 成人推荐相对更重视减少全身糖皮质激素使用及加重相关结局,对哮喘控制微小差异重视较低。
  • 青少年两种方案平衡非常接近且数据更有限,故两者均可。
  • 按需ICS/福莫特罗在轻度哮喘多个结局有获益,而按需SABA在无抗炎治疗时存在风险。

关键数值与推荐

  • 成人:按需ICS/福莫特罗替代规律ICS维持加按需SABA(条件推荐,低确定性证据)。
  • 青少年:按需ICS/福莫特罗或ICS维持加按需SABA均可(条件推荐,低确定性证据)。
  • 成人及青少年:按需ICS/福莫特罗替代按需SABA(强推荐,低确定性证据)。

临床怎么用

  • 成人轻度哮喘可优先考虑按需ICS/福莫特罗而非规律ICS维持加按需SABA。
  • 成人及青少年轻度哮喘应避免单用按需SABA,改用按需ICS/福莫特罗。
  • 青少年轻度哮喘可在按需ICS/福莫特罗与ICS维持加按需SABA间个体化选择。

局限性

  • 推荐实施受限于部分国家(包括欧盟国家)按需ICS/福莫特罗未获批用于轻度哮喘。
  • 证据确定性低。
  • 青少年数据更有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent clinical trials of as-needed fixed-dose combination of inhaled corticosteroid (ICS)/formoterol have provided new evidence that may warrant a reconsideration of current practice. A Task Force was set up by the European Respiratory Society to provide evidence-based recommendations on the use of as-needed ICS/formoterol as treatment for mild asthma. The Task Force defined two questions that were assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. The Task Force utilised the outcomes to develop recommendations for a pragmatic guideline for everyday clinical practice. The Task Force suggests that adults with mild asthma use as-needed ICS/formoterol instead of regular ICS maintenance treatment plus as-needed short-acting β2-antagonist (SABA) and that adolescents with mild asthma use either as-needed ICS/formoterol or ICS maintenance treatment plus as-needed SABA (conditional recommendation; low certainty of evidence). The recommendation for adults places a relatively higher value on the reduction of systemic corticosteroid use and the outcomes related to exacerbations, and a relatively lower value on the small differences in asthma control. Either treatment option is suggested for adolescent patients as the balance is very close and data more limited. The Task Force recommends that adult and adolescent patients with mild asthma use as-needed ICS/formoterol instead of as-needed SABA (strong recommendation; low certainty of evidence). This recommendation is based on the benefit of as-needed ICS/formoterol in mild asthma on several outcomes and the risks related to as-needed SABA in the absence of anti-inflammatory treatment. The implementation of this recommendation is hampered in countries (including European Union countries) where as-needed ICS/formoterol is not approved for mild asthma.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Papi A, Ferreira DS, Agache I, et al. European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma. Eur Respir J. 2023. PMID: 37678955. doi:10.1183/13993003.00047-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。